SCHEMBL4028624

SCHEMBL4028624

COC(=O)Cc1nc2ccccc2s1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.62
KMT2A Q03164 5/20 0.62
MEN1 O00255 4/20 0.62
KDM4E B2RXH2 2/20 0.62
GAA P10253 1/20 0.62
CYP1A2 P05177 1/20 0.60
CYP2C19 P33261 1/20 0.60
ALDH1A1 P00352 5/20 0.56
POLB P06746 2/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
SMN1; SMN2 Q16637 3/20 0.55
HPGD P15428 1/20 0.55
ALOX15 P16050 2/20 0.54
TSHR P16473 1/20 0.54
RECQL P46063 1/20 0.54
HSD17B10 Q99714 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
HTT P42858 2/20 0.53
PKM P14618 1/20 0.53
ADORA1 P30542 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL6428429 0.98 MAPT (0.60) MAPTKMT2AMEN1KDM4EGAA
SCHEMBL12210184 0.86 HTT (0.55) MAPTKMT2AMEN1KDM4EGAA
SCHEMBL7635641 0.85 MAPT (0.75) MAPTKMT2AMEN1KDM4EGAA
SCHEMBL29647831 0.85 MAPT (0.75) MAPTKMT2AMEN1KDM4EGAA
SCHEMBL3100413 0.85 MAPT (0.75) MAPTKMT2AMEN1KDM4EGAA
SCHEMBL18256154 0.85 MAPT (0.72) MAPTKMT2AMEN1GAAALDH1A1
SCHEMBL5256099 0.82 SMN1; SMN2 (0.70) MAPTKMT2AMEN1KDM4ECYP1A2
SCHEMBL1398257 0.82 MAPT (0.67) MAPTKMT2AMEN1KDM4EGAA
SCHEMBL6642379 0.81 HTT (0.64) MAPTKMT2AMEN1ALDH1A1POLB
SCHEMBL11469068 0.81 MAPT (0.55) MAPTKMT2AMEN1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009100403-A1 SUBSTITUTED ARYL PYRIMIDINONES NEUROGEN CORPORATION (US) 2009-08-13 WO disclosed
US-7569337-B2 Labeling brain tissues in vivo or in vitro; 3-Benzothiazol-2-yl-7-[4-(2-fluoro-ethyl)-piperazin-1-yl]-chromen-2-one; diagnosis, monitoring the effectiveness of a therapeutic treatment and detecting histopathological hallmarks of Alzheimer's disease NOVARTIS AG (CH) 2009-08-04 US disclosed
EP-1483262-B1 COUMARINES USEFUL AS BIOMARKERS NOVARTIS AG (CH) 2007-11-14 EP disclosed
US-20050169837-A1 Coumarines useful as biomarkers NOVARTIS AG (CH) 2005-08-04 US disclosed
EP-1483262-A1 COUMARINES USEFUL AS BIOMARKERS Novartis AG (CH) 2004-12-08 EP disclosed
WO-2003074519-A1 COUMARINES USEFUL AS BIOMARKERS NOVARTIS AG (CH) 2003-09-12 WO disclosed
US-5501980-A Benzazolylcoumarin-based ion indicators MOLECULAR PROBES, INC. (US) 1996-03-26 US disclosed
US-4578469-A COUMARIN DYES HOECHST AKTIENGESELLSCHAFT (DE) 1986-03-25 US disclosed
US-4113718-A Basic azo dyes CIBA-GEIGY CORPORATION (US) 1978-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050169837-A1 Coumarines useful as biomarkers CCNB1, CBR1, CYP1A1 MAPT 4068/4885KMT2A 2834/4885MEN1 2289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.